Article
BMC has published a full read literture review of pharmacological pain management in rheumatoid arthritis, pointing out that the best evidence for pain control comes from the use of DMARDs and treat-to-target strategies.
All News
Article
The British Society for Rheumatology has published its guideline for the management of adult and juvenile onset Sjogren's disease.
Article
JAMA has published a University of Minnesota cross-sectional study showing early adult (ages 25-44) mortality in the U.S. has risen substantially between 2011 to 2019 and 2020 to 2023. The largest portion of 2023 excess mortality was driven by drug poisoning, but many other external and natural causes exceeded what prior trends would have projected.
Article
A technique now widely used in sports medicine to speed recovery from leg injuries helped reduce symptoms and improve function in people with osteoarthritis (OA) of the knee, a randomized trial showed.
Dr. John Cush
Tweet
How did Rheumatology go from being the happiest specialist to now being 5th from the bottom at 65%? Top heavy happiness seems to be influenced by income? what do you think?
Allergy 94%
Pathology 88%
Dermatology 87% ....
Rheum 67%
Internal med 66%... https://t.co/YTKMElL868 https://t.co/RnsIVYWBFo
Dr. John Cush
Tweet
Target Trial Emulation Study from EUSTAR - Adding po glucocorticoids (<20mg/d Pred) to immunosuppressives to 208 early diffuse systemic sclerosis pts does not improve skin scores. 12 mos mRSS change similar (-2.7 vs -3.1); same w/ shorter dz (≤ 24 mos) or w/ mRSS ≤22.… https://t.co/QVbhFOEfIk https://t.co/9GrRpaWenh
Dr. John Cush
Tweet
A 3rd Actemra biosimilar was approved by the FDA - Celltrion announced approval of its 7th biosimilar, Avtozma (CT-P47, tocilizumab-anoh); both IV & SCm for Rx of RA, GCA, pJIA, Still's dz & Covid-19. Joins other IL-6 biosimilars Tofidence (Biogen 10/23) & Tyenne (Frensius 3/24)… https://t.co/UtG9YOXUX2 https://t.co/j3LzG7beys
Dr. John Cush
Tweet
Congratulations to 2025 Crafoord Prize (in Polyarthritis) laureates Christopher Goodnow, (UNSW Sydney, Australia), and David Nemazee (Scripss,, USA) for their work on tolerance checkpoints - prevent B cells from attacking the body’s own tissues in autoimmune diseases… https://t.co/WSyXVIFJa1 https://t.co/JtBau2JSvo
Dr. John Cush
Tweet
Celecoxib Lowers Colon Cancer Recurrence Risk
The Alliance for Clinical Trials in Oncology today announced the results of a data analysis from a randomized phase III clinical trial involving patients with stage III colon cancer, which found that adding the drug celecoxib to… https://t.co/tIoMtRlwKt https://t.co/fzOAplwJLi
Dr. John Cush
Tweet
Full read review and overview of Fibromyalgia - manifestations, pathophysiology, treatments and guidelines. Multidisciplinary, patient-centered treatment should includes a combination of pharmacological and nonpharmacological options. https://t.co/Go5T9pN6wH https://t.co/CIXai9OhZd
Dr. John Cush
Tweet
UK NHS 2023-24 figures show hospitalization for SLE is 8X more common in blacks (62.6 per 100,000) compared to white SLE (7.8/100K) and Asian SLE (26/100K), Lupus hospitalizations risen 50% in 4 yrs (6,334 to 8,006 in 2023-24). Is this “stark” inequality from delayed Dx?… https://t.co/NDdIkWKZy5 https://t.co/E4Fmvz9uLn
Dr. John Cush
Tweet
RHEUMS! Please check out this important Survey on Cannibis/THS/CBD use in Rheumatology. This is a short survey (Ive done it) from the Rheumatology Research Foundation, FORWARD and the National Databank folks. We need to know more here; especially from you1 Link:… https://t.co/0KYbgqvceq https://t.co/JeO8hV0luB
Dr. John Cush
Tweet
FDA has approved Journavx (suzetrigine) 50 mg tablets, 1st in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx reduces pain by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system, before pain signals… https://t.co/xKy7JY7pPr https://t.co/VYrDMQcjHc
Dr. John Cush
Tweet
Cross-sectional study of 50 SLE patients, 24% had fibromyalgianess, and 18% experienced widespread pain. Fibromyalgianess in SLE patients primarily reflects heightened pain sensitivity and symptom severity rather than SLE disease activity. https://t.co/oLYc4IsIpN https://t.co/eHVIe9OXVF
Dr. John Cush
Tweet
Screening for #RA-Machine learning algorithm applied to primary healthcare pts shown to correctly identify early RA based on 11 features (RF, CRP, ESR, SUA, HB, PLT, AMS, age, SJC TJC, deformity) w/ 96% specificity, 96% sensitivity, 96% AUC. https://t.co/Q25yvDwdJZ https://t.co/CTESAl6hSf
Dr. John Cush
Tweet
Infectious Sacroiliitis
A large Chinese cohort study of patients with infectious sacroiliitis (SI) suggests that CT-guided biopsy of the sacroiliac joint is necessary to properly identify the infectious pathogen leading to SI.
https://t.co/GYI8iz0rOS https://t.co/3wQR47Wd4g
Dr. John Cush
Tweet
Orthotics in Rheumatoid Arthritis
RA is a chronic inflammatory disease affecting synovial joints, often in the hands and feet. Due to its progressive inflammatory nature, RA can lead to impairment of function, reduced quality of life, significant joint pain, disability, and… https://t.co/Tqf5YsSFX3 https://t.co/imnPyNXXkq
Dr. John Cush
Tweet
Adalimumab Withdrawal in Uveitis Patients
Adalimumab is an effective treatment for JIA-associated uveitis and has been FDA approved for such use - but for how long and can the drug be withdrawn? An adalimumab (ADA) withdrawal trial has shown recurrence of uveitis, arthritis, or… https://t.co/J1CRgC3GJz https://t.co/8eOSvl5zZm
Dr. John Cush
Tweet
JAMA Case: 58-Year-Old Woman With Urticaria, Fever, and Joint Pain. 2 yrs daily fatigue, arthralgia (hands, feet, shoulders, knees), myalgia, intermittent fevers (>38.5°C). NL CBC, CRP 20.9 mg/L. negative dsDNA, ANCA, ENA, nl LFTs. What do you do next?… https://t.co/aY70tEhJ5Y https://t.co/QaK1G7RJkp
Dr. John Cush
Tweet
🚨 Join us for the 7th Annual RheumNow Live 2/8 - 2/9 : Where Innovation Meets Impact in Rheumatology! 🚨
🗓 2025| In-Person & Virtual
💻 Virtual: Stream + Q&A access (spots still open!)
Don’t miss the rheumatology event of the year!
👉 Register today:… https://t.co/Rf4U6JcdKs https://t.co/ilG2M7aRYS
